NorthWest Biotherapeutics Inc (NWBO)

[WojD40]

I had a similar thought recently. If we were to be purchased at a premium, the Buyer might want to keep all the media powder dry and have their name - rather than NWBO's - associated with the DCVax breakthrough.

What I don't understand is how a binding agreement can exist between The Journal and The Company. Is it normal to have the trial sponsor embargoed? I understand an embargo against publishing details of the scientific article[/I] under review, but the results themselves? It only makes sense if this is a strategic (artificial) delay in order to move 'all at once'.

I'm hugely excited for the near future, but I no longer buy the idea that 'the results and trial were so complicated' that it needed a peer review (which was the standard narrative here over the past two years). The May 10th presentation was unambiguous.

Something happened almost exactly two years ago...in between announcing in August 2020 that data will be revealed in September of that year, and Oct 5 2020 which ushered in this unprecedented twenty four month delay in 'official' TLD.

Can anyone jog my memory as to the dilution over the past two years? My instinct is that it was all the exercising of previously held warrants, rather than offerings, but I may be wrong. If there were informal M&A talks two years ago, it would've made sense for the company to go dark and begin to dot the i's and cross the t's, knowing it could finance operations quietly with warrants that would be exercised anyway.

My final thought about why a buyout is on the cards is the fact that this company - who will be ready and approved for commercial manufacturing in the UK by the end of the year - still has not hired the dozens and dozens of marketing and finance and logistics people necessary for such an enterprise. They are still acting as if they won't exist in January (in a good way). Would love to hear some counterarguments to this.

If we get an ASM proxy and there is no shelf increase then we've been bought, surely.